Heartport was the darling of investors when it burst on the scene in 1996 with a new minimally-invasive cardiac surgery technology. The company's stratospheric IPO valuation quickly deflated as cardiac surgeons, proving more cautious than investors, have been slow in adopting Heartport's technique. Armed with new management and a new strategy, Heartport is regrouping, still convinced, in the face of major competitors using a different approach, that its technology represents the future of minimally-invasive cardiac surgery.
by Stephen Levin
On April 6, 1998, 83-year-old Fayard Nicholas, half of the famed Nicholas Brothers tap dancing duo, joined his brother Harold...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.